IBDEI080 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3606,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,3606,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,3606,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,3607,0)
 ;;=203.00^^33^281^96
 ;;^UTILITY(U,$J,358.3,3607,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3607,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,3607,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,3607,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,3608,0)
 ;;=203.01^^33^281^95
 ;;^UTILITY(U,$J,358.3,3608,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3608,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,3608,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,3608,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,3609,0)
 ;;=238.6^^33^281^99
 ;;^UTILITY(U,$J,358.3,3609,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3609,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,3609,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,3609,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,3610,0)
 ;;=205.00^^33^281^4
 ;;^UTILITY(U,$J,358.3,3610,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3610,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,3610,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,3610,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,3611,0)
 ;;=205.01^^33^281^3
 ;;^UTILITY(U,$J,358.3,3611,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3611,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,3611,1,5,0)
 ;;=5^AML In Remission
 ;;^UTILITY(U,$J,358.3,3611,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,3612,0)
 ;;=205.10^^33^281^15
 ;;^UTILITY(U,$J,358.3,3612,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3612,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,3612,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,3612,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,3613,0)
 ;;=205.11^^33^281^14
 ;;^UTILITY(U,$J,358.3,3613,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3613,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,3613,1,5,0)
 ;;=5^CML In Remission
 ;;^UTILITY(U,$J,358.3,3613,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,3614,0)
 ;;=289.0^^33^281^48
 ;;^UTILITY(U,$J,358.3,3614,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3614,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,3614,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,3614,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,3615,0)
 ;;=238.4^^33^281^100
 ;;^UTILITY(U,$J,358.3,3615,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3615,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,3615,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,3615,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,3616,0)
 ;;=V58.61^^33^281^113
 ;;^UTILITY(U,$J,358.3,3616,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3616,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,3616,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,3616,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,3617,0)
 ;;=282.49^^33^281^105
 ;;^UTILITY(U,$J,358.3,3617,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3617,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,3617,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,3617,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,3618,0)
 ;;=289.89^^33^281^11
 ;;^UTILITY(U,$J,358.3,3618,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3618,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,3618,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,3618,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,3619,0)
 ;;=238.79^^33^281^79
 ;;^UTILITY(U,$J,358.3,3619,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3619,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,3619,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis NEC
 ;;^UTILITY(U,$J,358.3,3619,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,3620,0)
 ;;=287.30^^33^281^101
 ;;^UTILITY(U,$J,358.3,3620,1,0)
 ;;=^358.31IA^5^2
